Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS)

BACKGROUND: The rare disease, Hunter Syndrome (mucopolysaccharidosis type II; MPS II), characterized by iduronate-2-sulfatase deficiency, has heterogeneous symptoms often including cognitive impairment (CI). To evaluate physical functioning and daily activity limitations of patients with MPS II, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattera, Maria, Vernon, Margaret K., Raluy-Callado, Mireia, Mikl, Jaromir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225555/
https://www.ncbi.nlm.nih.gov/pubmed/30409228
http://dx.doi.org/10.1186/s12955-018-1006-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225555/
https://www.ncbi.nlm.nih.gov/pubmed/30409228
http://dx.doi.org/10.1186/s12955-018-1006-8

Ejemplares similares